Undifferentiated connective tissue disease medical therapy

The pharmacologic medical therapy is recommended based on the rheumatic disease pattern manifested by the patient such as methotrexate in those exhibiting arthritis and dermatitis. Supportive therapy includes; avoiding cold exposure in those experiencing Raynaud’s phenomenon, avoiding sun in photosensitivity, non-steroidal anti-inflammatory drugs for pain control, sunscreen used for photosensitivity, and emollients for dry skin and rash.

• Avoiding cold exposure in those experiencing Raynaud’s phenomenon
• Avoiding sun in photosensitivity

• Non-steroidal anti-inflammatory drugs for pain control
• Sunscreen used for photosensitivity
• Emollients for dry skin, rash

• Oral regimen
  • Preferred regimen (1): Methotrexate 7.5 mg PO q24h for 6 months (not used for CNS symptoms or serositis)^[1]
    • Dose can be gradually increased to 13.6 mg after 6 months

Template:WH Template:WS